AI Accelerates Transformation in India's Pharmaceutical Sector

India's pharmaceutical sector is undergoing significant transformation through the integration of artificial intelligence (AI) across its value chain, encompassing drug discovery, manufacturing, and distribution. The nation, already the third-largest pharmaceutical producer by volume globally, is poised for substantial growth, with its market size expected to reach USD 174.67 billion by 2034, heavily influenced by AI adoption.

AI applications in India's pharmaceutical landscape are diverse, focusing on accelerating drug discovery and development, enhancing supply chain management, improving quality control, enabling personalized healthcare, and ensuring regulatory compliance. Notably, half of India's pharmaceutical firms are exploring generative AI (GenAI) initiatives, with a quarter already deploying AI solutions in live operations, indicating rapid uptake.

In drug discovery, AI platforms analyze vast datasets to identify novel drug candidates and predict their efficacy, significantly reducing the time and cost compared to traditional methods. Machine learning tools are instrumental in scanning millions of molecules and modeling interactions. Collaborative efforts, such as the AI in Healthcare Centre formed by IIT Delhi and AIIMS Delhi, are fostering indigenous AI solutions aimed at improving healthcare access and outcomes.

Furthermore, AI-powered predictive analytics are optimizing demand forecasting and inventory management, crucial for navigating the complexities of India's large and diverse population. The advancement of personalized medicine through AI allows for tailored treatments based on individual genetic and health data, enhancing treatment effectiveness and patient care. Initiatives like AI-driven clinical decision support systems are also assisting healthcare providers in making more informed treatment choices.